Abilify Maintena® (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder
· First FDA-approved, once-monthly, long-acting injectable for the maintenance monotherapy treatment of bipolar I disorder in adults1,2 · New indication for Abilify Maintena is based on studies evaluating efficacy and safety in adult patients with bipolar I disorder1 Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena® (aripiprazole) for extended-release injectable suspension was approved by the U.S. Food and Drug Administration for the maintenance monotherapy treatment of bipolar I